Lexeo Therapeutics (LXEO) Form 3: CFO Louis Tamayo Reports No Holdings

Lexeo Therapeutics reported an initial Section 16 Form 3 for Louis Edward Tamayo, who is identified as Chief Financial Officer and an officer/director of the company.

Accepted by SEC EDGAR 08/27/2025 - 06:51 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Lexeo Therapeutics reported an initial Section 16 Form 3 for Louis Edward Tamayo, who is identified as Chief Financial Officer and an officer/director of the company. The form, with an event date of 08/15/2025, shows no securities beneficially owned by the reporting person at the time of filing. The filing was signed by an attorney-in-fact on 08/27/2025.

Positive

• Form 3 filed to disclose initial officer reporting status
• Reporting person identified as Chief Financial Officer (Louis Edward Tamayo)

Negative

• No securities beneficially owned reported on initial Form 3
• Potential lack of equity alignment between CFO and shareholders at filing date

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lexeo Therapeutics' (LXEO) Form 3 filed by the CFO report?

The Form 3 for Louis Edward Tamayo reported no securities beneficially owned and identified him as Chief Financial Officer; the event date is 08/15/2025.

When was the event date and signature date on the LXEO Form 3?

The event requiring the statement is dated 08/15/2025 and the form shows a signature by an attorney-in-fact dated 08/27/2025.

Does the Form 3 show any derivative or equity holdings for LXEO CFO Tamayo?

No. The filing explicitly states no securities are beneficially owned; both non-derivative and derivative sections list no holdings.

What is the reporting relationship of Louis Edward Tamayo to Lexeo (LXEO)?

The form indicates the reporting person is a company Officer with the title Chief Financial Officer and is also marked as a Director.

Was the Form 3 filed jointly or by a single reporting person?

The filing indicates it was filed by one reporting person (single filer).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tamayo Louis Edward

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NY 10010

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/15/2025

3. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Youjin Choi, Attorney-in-Fact	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.